Novo Nordisk gearing up for pan-India ... undergoing trials for fatty liver (MASH) and chronic kidney diseases. Preliminary clinical results show that Wegovy reduces fatty liver by 37 per cent and ...

Danish pharma giant Novo Nordisk on Tuesday launched its blockbuster weight loss drug Wegovy as a once-a-week injection in ...

Novo Nordisk has officially launched its anti-obesity drug Wegovy in India ahead of patent expiry. This move aims to tackle rising obesity rates while facing competition from rival drugs.

Danish pharma giant Novo Nordisk’s announcement comes months after launch of another top selling obesity drug Mounjaro in ...

The achievement of that goal in India, which ranks third in obesity numbers after the US and China, will shatter the record ...

They have been called miraculous and the fastest way to lose weight. From Wegovy to Mounjaro, here’s how GLP-1 drugs work ...

The first diabetes and obesity pill that is similar to Ozempic — but in tablet form — may actually outperform the popular ...

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

CMS’ drug price negotiations are advancing, but new indications and exclusivity rules could complicate future pricing cycles. CMS gained the authority to negotiate list prices with drug manufacturers ...

Novo Nordisk NVO shares have gained 5.8% in a week. The uptrend in the stock price was driven by reports of an activist hedge ...

With many different species entering torpor for a variety of reasons, scientists are looking to their sleepy secrets for ways ...